130 related articles for article (PubMed ID: 1954180)
41. [The value of neuroendocrine markers for response to therapy and survival in patients with advanced non-small cell lung cancer].
Petrović M; Ilić N; Baskić D
Srp Arh Celok Lek; 2010; 138(1-2):37-42. PubMed ID: 20422910
[TBL] [Abstract][Full Text] [Related]
42. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
43. [Prognostic value of neuron enolase levels in serum of patients with lung neoplasms].
Jassem E; Gan J; Cynowska B
Pneumonol Alergol Pol; 1995; 63(7-8):415-20. PubMed ID: 8520560
[TBL] [Abstract][Full Text] [Related]
44. Spindle cell carcinoids of the lung with paraganglioid features: a reappraisal of their histogenetic origin from paraganglia using immunohistochemical and electronmicroscopic techniques.
Min KW
Ultrastruct Pathol; 2001; 25(3):207-17. PubMed ID: 11465477
[TBL] [Abstract][Full Text] [Related]
45. [Pheochromocytoma--pathohistologic and immunohistochemical aspects].
Tatić S; Havelka M; Paunović I; Bozić V; Diklic A; Brasanac D; Janković R; Jancić-Zguricas M
Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():7-13. PubMed ID: 12584991
[TBL] [Abstract][Full Text] [Related]
46. Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations.
Suh KJ; Keam B; Kim M; Park YS; Kim TM; Jeon YK; Kim DW; Chung DH; Kim YW; Heo DS
Clin Lung Cancer; 2016 Jul; 17(4):245-252.e1. PubMed ID: 26719155
[TBL] [Abstract][Full Text] [Related]
47. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma.
Fizazi K; Cojean I; Pignon JP; Rixe O; Gatineau M; Hadef S; Arriagada R; Baldeyrou P; Comoy E; Le Chevalier T
Cancer; 1998 Mar; 82(6):1049-55. PubMed ID: 9506348
[TBL] [Abstract][Full Text] [Related]
48. Immunohistochemical study of neuroendocrine differentiation in primary glandular lesions and tumors of the urinary bladder.
Bollito ER; Pacchioni D; Lopez-Beltran A; Volante M; Terrone C; Casetta G; Mari M; DePompa R; Cappia S; Papotti M
Anal Quant Cytol Histol; 2005 Aug; 27(4):218-24. PubMed ID: 16220833
[TBL] [Abstract][Full Text] [Related]
49. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?
Angelsen A; Syversen U; Haugen OA; Stridsberg M; Mjølnerød OK; Waldum HL
Prostate; 1997 Jan; 30(1):1-6. PubMed ID: 9018329
[TBL] [Abstract][Full Text] [Related]
50. Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy.
Quoix E; Purohit A; Faller-Beau M; Moreau L; Oster JP; Pauli G
Lung Cancer; 2000 Nov; 30(2):127-34. PubMed ID: 11086206
[TBL] [Abstract][Full Text] [Related]
51. [Multidrug resistance and its relationship with neuroendocrine differentiation in non-small cell lung carcinoma].
Yu SP; Xiong YY; Tian SF
Zhonghua Jie He He Hu Xi Za Zhi; 2003 Mar; 26(3):165-8. PubMed ID: 12816683
[TBL] [Abstract][Full Text] [Related]
52. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer.
Pujol JL; Quantin X; Jacot W; Boher JM; Grenier J; Lamy PJ
Lung Cancer; 2003 Feb; 39(2):131-8. PubMed ID: 12581564
[TBL] [Abstract][Full Text] [Related]
53. Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy.
Kamiya N; Akakura K; Suzuki H; Isshiki S; Komiya A; Ueda T; Ito H
Eur Urol; 2003 Sep; 44(3):309-14; discussion 314. PubMed ID: 12932928
[TBL] [Abstract][Full Text] [Related]
54. Neuron specific enolase expression in carcinoma of the lung.
Reeve JG; Stewart J; Watson JV; Wulfrank D; Twentyman PR; Bleehen NM
Br J Cancer; 1986 Apr; 53(4):519-28. PubMed ID: 3011053
[TBL] [Abstract][Full Text] [Related]
55. Immunohistochemical positivity for neuron-specific enolase and Leu-7 in malignant mesotheliomas.
Mayall FG; Jasani B; Gibbs AR
J Pathol; 1991 Dec; 165(4):325-8. PubMed ID: 1723753
[TBL] [Abstract][Full Text] [Related]
56. Pro-gastrin-releasing peptide and neuron-specific enolase: useful predictors of response to chemotherapy and survival in patients with small cell lung cancer.
Huang Z; Xu D; Zhang F; Ying Y; Song L
Clin Transl Oncol; 2016 Oct; 18(10):1019-25. PubMed ID: 26886220
[TBL] [Abstract][Full Text] [Related]
57. Small-cell neuroendocrine carcinoma of the ampullary region. A clinicopathologic, immunohistochemical, and ultrastructural study of three cases.
Zamboni G; Franzin G; Bonetti F; Scarpa A; Chilosi M; Colombari R; Menestrina F; Pea M; Iacono C; Serio G
Am J Surg Pathol; 1990 Aug; 14(8):703-13. PubMed ID: 1696069
[TBL] [Abstract][Full Text] [Related]
58. [Clinical and prognostic significance of tumor markers cytokeratin 19 fragment, carcinoembryonic antigen, and neuron-specific enolase in lung cancer].
Zemaitis M; Sakalauskas R; Malakauskas K; Muley T; Fischer JR; Lahm H
Medicina (Kaunas); 2005; 41(7):566-76. PubMed ID: 16062024
[TBL] [Abstract][Full Text] [Related]
59. Secretagogin is a new neuroendocrine marker in the human prostate.
Adolf K; Wagner L; Bergh A; Stattin P; Ottosen P; Borre M; Birkenkamp-Demtröder K; Orntoft TF; Tørring N
Prostate; 2007 Apr; 67(5):472-84. PubMed ID: 17285592
[TBL] [Abstract][Full Text] [Related]
60. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
